Dr. Rehman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7247 West Central
Toledo, OH 43617Phone+1 419-408-2249
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Allergy and Immunology, 1992
- Rush University Medical CenterResidency, Pediatrics, 1987 - 1990
- Dow University of Health SciencesClass of 1983
Certifications & Licensure
- CA State Medical License 1991 - Present
- OH State Medical License 1996 - 2029
- MI State Medical License 1996 - 2025
- WV State Medical License 1992 - 1999
- IL State Medical License 1988 - 1990
- American Board of Allergy and Immunology Allergy & Immunology
Clinical Trials
- A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Start of enrollment: 2012 Jan 27
- Octagam 5% Versus Comparator Post Marketing Trial Start of enrollment: 2013 May 21
- Study of Octanorm Subcutaneous IG in Patients With PID Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsLong-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.Roger H Kobayashi, Jiří Litzman, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi
Clinical and Experimental Immunology. 2022-12-15 - Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig]) in the treatment of patients with primary immu...Roger H Kobayashi, Sudhir Gupta, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi
Frontiers in Immunology. 2022-01-01 - 4 citationsTreatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).Roger H. Kobayashi, Jose Fernando Mandujano, Syed M. Rehman, Ai Lan Kobayashi, Bob Geng
Immunotherapy. 2021-05-06
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: